Fig. 6: Treatment with lonafarnib circumvents resistance to sunitinib in a xenograft model of human ccRCC. | British Journal of Cancer

Fig. 6: Treatment with lonafarnib circumvents resistance to sunitinib in a xenograft model of human ccRCC.

From: CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma

Fig. 6

PNX0010 subcutaneous xenograft tumours were established in 6-week-old male C.B17/Icr-scid mice. The mice were treated orally three times per week with: (i) 10% 2-hydroxypropyl-β-cyclodextrin in PBS (control); (ii) sunitinib (40 mg/kg); (iii) lonafarnib (40 mg/kg); (iv) sunitinib and lonafarnib combined. Tumour volumes were calculated as described in “Methods”. Values are means (n = 5) ± SD. *P < 0.05; **P < 0.001; ***P < 0.0001.

Back to article page